一种用于个性化治疗组合的系统生物学方法。
A systems biology approach to personalizing therapeutic combinations.
作者信息
Kwong Lawrence N, Heffernan Timothy P, Chin Lynda
机构信息
1Department of Genomic Medicine and 2Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Cancer Discov. 2013 Dec;3(12):1339-44. doi: 10.1158/2159-8290.CD-13-0394.
Abstract
The identification of evidence-based, efficacious drug combinations for each cancer, among thousands of potential permutations, is a daunting task. In this perspective, we propose a systematic approach to defining such combinations by molecularly benchmarking a drug against a desired state of efficacy using model systems.
摘要
在数千种可能的组合中，为每种癌症确定基于证据的有效药物组合是一项艰巨的任务。从这个角度来看，我们提出了一种系统的方法，通过使用模型系统将一种药物与期望的疗效状态进行分子层面的对比，来定义此类组合。
相似文献
1
A systems biology approach to personalizing therapeutic combinations.一种用于个性化治疗组合的系统生物学方法。
Cancer Discov. 2013 Dec;3(12):1339-44. doi: 10.1158/2159-8290.CD-13-0394.
2
Network medicine: finding the links to personalized therapy.网络医学：寻找通向个体化治疗的联系。
Clin Pharmacol Ther. 2013 Dec;94(6):613-6. doi: 10.1038/clpt.2013.195.
3
Combinations of targeted therapies in human cancers.人类癌症中靶向治疗的联合应用。
Aging (Albany NY). 2016 Oct 26;8(10):2258-2259. doi: 10.18632/aging.101085.
4
Future of personalized medicine in oncology: a systems biology approach.肿瘤个性化医学的未来：系统生物学方法。
J Clin Oncol. 2010 Jun 1;28(16):2777-83. doi: 10.1200/JCO.2009.27.0777. Epub 2010 Apr 20.
5
Network medicine in disease analysis and therapeutics.网络医学在疾病分析和治疗中的应用。
Clin Pharmacol Ther. 2013 Dec;94(6):627-9. doi: 10.1038/clpt.2013.181.
6
Computing cancer's weak spots.计算癌症的薄弱点。
Science. 2020 Jun 12;368(6496):1174-1177. doi: 10.1126/science.368.6496.1174.
7
Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.实体瘤中靶向药物与化疗有效及拮抗联合用药的生物学见解。
Cancer Metastasis Rev. 2014 Mar;33(1):295-307. doi: 10.1007/s10555-013-9451-7.
8
In silico drug combination discovery for personalized cancer therapy.用于个性化癌症治疗的计算机辅助药物组合发现
BMC Syst Biol. 2018 Mar 19;12(Suppl 2):16. doi: 10.1186/s12918-018-0546-1.
9
Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.基于系统药理学通过靶向癌症突变基因发现用于精准肿瘤学的天然产物
CPT Pharmacometrics Syst Pharmacol. 2017 Mar;6(3):177-187. doi: 10.1002/psp4.12172. Epub 2017 Mar 14.
10
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.网络驱动的癌症细胞头像用于发现组合药物和鉴定 DNA 损伤反应抑制剂的生物标志物。
NPJ Syst Biol Appl. 2024 Jun 21;10(1):68. doi: 10.1038/s41540-024-00394-w.
引用本文的文献
1
Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery.用于组合药物发现的扰动基因表达特征
iScience. 2019 May 31;15:291-306. doi: 10.1016/j.isci.2019.04.039. Epub 2019 May 4.
2
Combine and conquer: challenges for targeted therapy combinations in early phase trials.联合并攻克：早期试验中靶向治疗联合方案面临的挑战
Nat Rev Clin Oncol. 2017 Jan;14(1):57-66. doi: 10.1038/nrclinonc.2016.96. Epub 2016 Jul 5.
本文引用的文献
1
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.联合靶向 MEK 和 PI3K/mTOR 效应通路对于有效抑制NRAS 突变型黑色素瘤的体外和体内研究是必要的。
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19.
2
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.BRAF 抑制与转移性黑色素瘤患者中黑色素瘤相关抗原表达增强和更有利的肿瘤微环境相关。
Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10.
3
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.联合 BCL-XL 和 MEK 抑制的合成致死相互作用促进 KRAS 突变型癌症模型中的肿瘤消退。
Cancer Cell. 2013 Jan 14;23(1):121-8. doi: 10.1016/j.ccr.2012.11.007. Epub 2012 Dec 13.
4
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.高通量药物筛选鉴定的黑色素瘤基因选择性联合治疗方法。
Cancer Discov. 2013 Jan;3(1):52-67. doi: 10.1158/2159-8290.CD-12-0408. Epub 2012 Dec 13.
5
Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals.ERK 活性的调频脉冲传递定量的增殖信号。
Mol Cell. 2013 Jan 24;49(2):249-61. doi: 10.1016/j.molcel.2012.11.002. Epub 2012 Dec 6.
6
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.致癌性NRAS 信号通路在黑色素瘤中差异调节存活和增殖。
Nat Med. 2012 Oct;18(10):1503-10. doi: 10.1038/nm.2941. Epub 2012 Sep 16.
7
A landscape of driver mutations in melanoma.黑色素瘤中的驱动基因突变全景。
Cell. 2012 Jul 20;150(2):251-63. doi: 10.1016/j.cell.2012.06.024.
8
Targeting BRAFV600E in an inducible murine model of melanoma.在诱导型黑色素瘤小鼠模型中靶向 BRAFV600E。
Am J Pathol. 2012 Sep;181(3):785-94. doi: 10.1016/j.ajpath.2012.06.002. Epub 2012 Jul 11.
9
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.抗癌药物的序贯应用通过重新布线细胞凋亡信号网络增强细胞死亡。
Cell. 2012 May 11;149(4):780-94. doi: 10.1016/j.cell.2012.03.031.
10
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.针对三阴性乳腺癌中靶向 MEK 抑制的激酶组的动态重编程。
Cell. 2012 Apr 13;149(2):307-21. doi: 10.1016/j.cell.2012.02.053.
Zotero 插件